4 stories mentioning HKG:6938Updated 27d ago
Every FINWIRES story that references HKG:6938, newest first.
Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.
Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.
Suzhou Ribo Life Science (HKG:6938) achieved another milestone under a research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, according to a Hong Kong bourse filing Wednesday.The companies are researching therapies for metabolic dysfunction-associated steatohepatitis, or MASH, a serious and progressive form of fatty liver disease.The milestone underscores the commercial potential of Ribo Life Science's siRNA platform, the firm said.
Suzhou Ribo Life Science (HKG:6938) said it submitted a phase 2b clinical trial application to the European Medicines Agency for its core product Vortosiran for stroke prevention in atrial fibrillation, according to a Tuesday Hong Kong bourse filing.Vortosiran targets factor XI to reduce clotting activity and may offer thromboembolic protection with lower bleeding risk, the filing said.
